Elevar Therapeutics

Elevar Therapeutics company information, Employees & Contact Information

Elevar Therapeutics is a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. Elevating Outcomes: We take a relentless and inventive approach towards developing and advancing next-generation, best-in-class therapies that have the potential to set new standards of care and improve treatment experiences. Evolving Therapeutic Potential: We identify areas where we can develop, build upon or evolve medicines that offer patients improved clinical outcomes. Engaging With Purpose: We are committed to engaging with the highest ethical standards, driven by a passion to address the underserved needs of patients, caregivers, and healthcare providers.

Company Details

Employees
47
Founded
-
Address
1 Bridge Plaza N,
Phone
(801) 303-7440
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Fort Lee, New Jersey
Looking for a particular Elevar Therapeutics employee's phone or email?

Elevar Therapeutics Questions

News

Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board - GlobeNewswire

Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board GlobeNewswire

HLB appoints Brian Kim as CEO of US subsidiary Elevar Therapeutics - The Korea Herald

HLB appoints Brian Kim as CEO of US subsidiary Elevar Therapeutics The Korea Herald

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewswire

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors GlobeNewswire

Elevar Therapeutics Announces CEO Transition and New Board Appointment - PR Newswire

Elevar Therapeutics Announces CEO Transition and New Board Appointment PR Newswire

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization - Yahoo Finance

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization Yahoo Finance

Camrelizumab Plus Rivoceranib Improves Survival vs Standard First-Line Care for HCC - The American Journal of Managed Care® (AJMC®)

Camrelizumab Plus Rivoceranib Improves Survival vs Standard First-Line Care for HCC The American Journal of Managed Care® (AJMC®)

Elevar Therapeutics moves corporate HQ to Fort Lee from Utah - ROI-NJ

Elevar Therapeutics moves corporate HQ to Fort Lee from Utah ROI-NJ

Elevar Therapeutics Appoints Gus Aromin as Vice President of Regulatory Affairs - PR Newswire

Elevar Therapeutics Appoints Gus Aromin as Vice President of Regulatory Affairs PR Newswire

Elevar Therapeutics Completes Merger Transaction with South Korean Company HLB - Wilson Sonsini

Elevar Therapeutics Completes Merger Transaction with South Korean Company HLB Wilson Sonsini

Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey - GlobeNewswire

Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey GlobeNewswire

Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar) - PR Newswire

Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar) PR Newswire

Elevar Therapeutics and Jiangsu Hengrui Pharma Announce - GlobeNewswire

Elevar Therapeutics and Jiangsu Hengrui Pharma Announce GlobeNewswire

Neopharma Forms Joint Venture With Elevar Therapeutics for Commercialization of Oncology NCE - PR Newswire

Neopharma Forms Joint Venture With Elevar Therapeutics for Commercialization of Oncology NCE PR Newswire

Jiangsu Hengrui Pharma and Elevar Therapeutics Announce - GlobeNewswire

Jiangsu Hengrui Pharma and Elevar Therapeutics Announce GlobeNewswire

Elevar Therapeutics Names Wade Smith Chief Financial Officer - GlobeNewswire

Elevar Therapeutics Names Wade Smith Chief Financial Officer GlobeNewswire

Elevar Therapeutics Announces FDA Acceptance of New Drug - GlobeNewswire

Elevar Therapeutics Announces FDA Acceptance of New Drug GlobeNewswire

Top Elevar Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant